IsoRay (NYSEAMERICAN:ISR) posted its quarterly earnings data on Thursday. The healthcare company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.02), Morningstar.com reports. The company had revenue of $1.92 million for the quarter, compared to the consensus estimate of $1.92 million.
IsoRay stock opened at $0.44 on Friday. IsoRay has a twelve month low of $0.27 and a twelve month high of $1.22.
A number of analysts have recently issued reports on the stock. HC Wainwright set a $1.00 price objective on shares of IsoRay and gave the stock a “buy” rating in a report on Thursday, February 14th. Zacks Investment Research downgraded shares of IsoRay from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th.
IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.
Further Reading: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.